title: Cost-effectiveness of viral hepatitis B & C treatment.
abstract: With the availability of effective antiviral therapies for chronic viral hepatitis B and C, cost-effectiveness studies have been performed to assess the outcomes and costs of these therapies to support health policy. It is now accepted that treatment of active CHB is cost-effective versus no treatment, although there are a variety of options. And with the new developments around CHC treatment and diagnostic tools it is of interest to both the clinician and policy makers to know both the costs and effects of these choices. The purpose of this article is to provide the reader with an insight into the recent treatment developments and cost-effectiveness issues related to chronic hepatitis B and C treatment, and an overview of recent cost-effectiveness studies evolving around HBV and HCV therapy.
authors.affiliation: Department of Global Health and Population, Harvard School of Public Health, Harvard University, Boston, USA. Electronic address: mtoy@hsph.harvard.edu.
authors.forename: Mehlika
authors.initials: M
authors.lastname: Toy
mesh_terms: D000998:Antiviral Agents / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D004470:Economics, Medical; D017048:Health Care Costs; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000191:economics*; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000191:economics*; D006801:Humans; D019057:Quality-Adjusted Life Years
chemical_list: D000998:Antiviral Agents
keywords: Cost-effectiveness; Hepatitis B; Hepatitis C; Treatment